Invigor Medical vs CVS MinuteClinic
Two GLP-1 desks, one scoreboard. We put Invigor Medical and CVS MinuteClinic head-to-head on the published Brief Score — the same six factors, scored the same way.
Invigor Medical
CVS MinuteClinic
The verdict
Invigor Medical takes this head-to-head.
Invigor Medical scores 88 to 59 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.
That doesn't make CVS MinuteClinic a bad call — it's best for readers who want walk-in or virtual glp-1 rx at minuteclinic; insurance-based, no monthly subscription. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Invigor Medical | CVS MinuteClinic | |
|---|---|---|
| Brief Score | 88/100 (B+) | 59/100 (C) |
| Semaglutide | $199/mo | Not disclosed |
| Tirzepatide | $339/mo | Not disclosed |
| Coverage | Not disclosed | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.
CVS MinuteClinic: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Keep comparing
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.